Prospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 28, 2017; 23(44): 7899-7905
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Table 3 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin+peg-interferon alfa-2a (Second group) n (%)
Baseline characteristics (n = 528)ETR (n = 526), overall ETR 0.9962SVR (n = 515), overall SVR 0.9791Relapse (n = 11), overall relapse rate = 2.09%
Age (yr)
≤ 40 (n = 419)419 (100)415 (99.05)4 (0.95)
> 40 (n = 109)107 (98.17)100 (93.46)7 (6.54)
Previous antiviral treatment history
Naïve (n = 399)399 (100)396 (99.25)3 (0.75)
Treated (n = 129)127 (98.45)119 (93.70)8 (6.30)
Gender
Male (n = 386)386 (100)382 (98.96)4 (1.04)
Female (n = 142)140 (98.59)133 (95)7 (5)